1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A-2
QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended: MARCH 31, 1996 Commission File Number: 0-19319
-------------- -------
VERTEX PHARMACEUTICALS INCORPORATED
-----------------------------------
(Exact name of registrant as specified in its charter)
MASSACHUSETTS
-------------
(State or other jurisdiction incorporation or organization)
04-3039129
----------
(I.R.S. Employer Identification No.)
130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242
-------------------------------------------------------
(Address of principal executive offices, including zip code)
617-577-6000
------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
YES X NO
--- ---
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
Class Outstanding at May 9, 1996
----- --------------------------
Common Stock, par value $.01 per share 17,368,453
2
PART II
OTHER INFORMATION
Item 6. Exhibits:
10.1 License Agreement and Supply Agreement, both dated May 9,
1996, between the Registrant and BioChem Pharma
(International) (filed herewith with certain confidential
information omitted).
10.2 Research and Development Agreement, dated April 13, 1993,
between the Registrant and Kissei Pharmaceutical Co., Ltd.*
- -------------------
*Filed as an exhibit to the Registrant's Quarterly Report on Form 10-Q/A for the
quarter ended March 31, 1996 and incorporated herein by reference. The
Registrant omitted portions of the Research and Development Agreement for which
it requested confidential treatment from the Securities and Exchange Commission.
The portions of that agreement for which confidential treatment has been
requested have been marked "Confidential Information Omitted" and have been
filed separately in unredacted form with the Securities and Exchange Commission.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf by the
undersigned thereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
Date: July 22, 1996 /s/ Thomas G. Auchincloss, Jr.
----------------------------------------
Thomas G. Auchincloss, Jr.
Senior Director of Finance and Treasurer
(Principal Financial Officer)
/s/ Hans D. van Houte
----------------------------------------
Hans D. van Houte
Controller
(Principal Accounting Officer)
4
Vertex Pharmaceuticals Incorporated has omitted portions of the attached License
Agreement and Supply Agreement for which it requested confidential treatment
from the Securities and Exchange Commission. The portions of those agreements
for which confidential treatment has been requested have been marked
"Confidential Information Omitted" and have been filed separately in unredacted
form with the Securities and Exchange Commission.